CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
AVM Biotechnology Inc
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Novartis
Viracta Therapeutics, Inc.
Oncternal Therapeutics, Inc
Shenzhen University General Hospital
Celgene
Astex Pharmaceuticals, Inc.
AO GENERIUM
Celgene
Takeda
Beijing Immunochina Medical Science & Technology Co., Ltd.
Incyte Corporation
AbbVie
Baylor College of Medicine
Amgen Research (Munich) GmbH
Baylor College of Medicine
Seagen Inc.
Asan Medical Center
M.D. Anderson Cancer Center